Therapy Areas: Central Nervous System
Orsini chosen as specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve)
3 December 2025 - Rare disease pharmacy solutions provider Orsini announced on Tuesday that it has been chosen as a specialty pharmacy partner for ITVISMA (onasemnogene abeparvovec-brve), an FDA-appro...
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering u...
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
7 November 2025 - Clinical-stage biotechnology company MavriX Bio and AS2Bio, a drug development accelerator established by the Foundation for Angelman Syndrome Therapeutics (FAST), announced on Thurs...
Precision NeuroMed's glioblastoma multiforme treatment granted FDA Orphan Drug Designation
8 October 2025 - Precision NeuroMed (PNM), a clinical-stage biotechnology company developing advanced drug delivery technologies for central nervous system (CNS) diseases, announced on Tuesday that th...
MapLight Therapeutics commences IPO
7 October 2025 - MapLight Therapeutics Inc, a California-based clinical-stage biopharmaceutical company focused on treatment for debilitating central nervous system disorders, said on Monday that it h...
SineuGene Therapeutics' ALS drug Investigational New Drug application receives Chinese regulatory approval
18 August 2025 - SineuGene Therapeutics Co, Ltd, a China-based, clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced on Friday that China�...